DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 1JJ — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 1JJ maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 1jj is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Dilated cardiomyopathy is defined by ventricular dilatation and poor systolic function, and it is the most common cause of chronic congestive heart failure and the most frequent indication for heart transplantation in young individuals. In the United States, up to 10,000 deaths every year have been attributed to cardiomyopathy, with 80% due to the dilated form. Variants in more than 50 genes have been associated with the disease, yet the aetiology of a large number of cases remains elusive. Mutations in genes for fibronectin, cytoskeletal proteins, and myosin in cardiomyocytes are considered to play a key role.
A 2025 review of 200 patients divided into three age groups highlights age-related features of manifestation, diagnosis, and treatment, with particular attention to individualisation of treatment based on age and comorbidities. Another 2025 review catalogues genes encoding contractile proteins and their regulatory elements in sarcomeres, Z-disks, cytoskeletons, desmosomes, and ion channels, and shows causal relationships of mutations with clinical scenarios including onset, structural myocardial disorders, arrhythmogenic complications, and progression of heart failure. Specific forms such as desmosomal-dependent cardiomyopathy, desmoplakin cardiomyopathy, and RBM20 cardiomyopathy are now recognised.
No abstract reports a clinical trial of a repurposed drug for dilated cardiomyopathy. No concrete survival or response rates are given in any abstract. The reviews consistently note that the aetiology of many cases remains unknown, and that genetic testing is argued for but not yet standardised into routine clinical management. What is still missing is a large, well-funded clinical trial that tests a specific repurposed drug in a genetically stratified patient population, along with the development of practical guidelines for integrating genetic testing into everyday care.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Cardiovascular Medicine · 2023 · 22 citations · open access
Comprehensive review on gene mutations contributing to dilated cardiomyopathy
AbstractDilated cardiomyopathy (DCM) is one of the most common primary myocardial diseases. However, to this day, it remains an enigmatic cardiovascular disease (CVD) characterized by ventricular dilatation, which leads to myocardial contractile dysfunction. It is the most common cause of chronic congestive heart failure and the most frequent indication for heart transplantation in young individuals. Genetics and various other factors play significant roles in the progression of dilated cardiomyopathy, and variants in more than 50 genes have been associated with the disease. However, the etiology of a large number of cases remains elusive. Numerous studies have been conducted on the genetic causes of dilated cardiomyopathy. These genetic studies suggest that mutations in genes for fibronectin, cytoskeletal proteins, and myosin in cardiomyocytes play a key role in the development of DCM. In this review, we provide a comprehensive description of the genetic basis, mechanisms, and research advances in genes that have been strongly associated with DCM based on evidence-based medicine. We also emphasize the important role of gene sequencing in therapy for potential early diagnosis and improved clinical management of DCM.
Current Opinion in Cardiology · 1991 · 1 citations
Dilated cardiomyopathy
AbstractDilated cardiomyopathy is the most common form of cardiomyopathy and is anatomically defined by large atrial and ventricular chambers, thin or normal myocardial walls, and poor systolic function. In the United States, up to 10,000 deaths every year have been determined to be secondary to cardiomyopathy, and of these 80% were due to the dilated form of the disease. This review describes recent advances of DCM, which can be grouped into the following headings: 1)etiologies and mechanisms of disease; 2) pathophysiology of the dilated heart; 3) diagnostic approaches; 4) clinical findings and prognosis; and 5) therapy.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
DILATED CARDIOMYOPATHY IN PATIENTS OF DIFFERENT AGE GROUPS DIAGNOSTIC AND TREATMENT FEATURES
AbstractDilated cardiomyopathy (DCM) is a severe myocardial disorder characterized by progressive dilation and dysfunction of the left ventricle, ultimately leading to heart failure. This article examines the age-related features of the manifestation, diagnosis, and treatment of DCM. The study is based on an analysis of data from 200 patients divided into three age groups. Key diagnostic markers are highlighted, including echocardiographic parameters and laboratory findings, as well as specific treatment approaches utilizing modern therapeutic strategies. Particular attention is paid to the individualization of treatment based on age and the presence of comorbidities.
Clinical and genetic heterogeneity of dilated cardiomyophathy. Review
AbstractThis article contains an overview of published scientific sources from the MEDLINE database on the PubMed, Web of Science, Scopus platforms regarding the dilated cardiomyopathy with an emphasis on clinical and genetic aspects. Taking into account the etiological origins, various classification categories of myocardial damages are presented — non‑syndromic, acquired (secondary), syndromic cardiomyopathies. The modern definition of dilated cardiomyophaty is presented in accordance with the recommendations of international experts. The review focuses on cardiomyocyte components that are important for energy generation and transmission, mechanical and signaling functions, and maintenance of electrolyte homeostasis. A list of genes encoding contractile proteins and their regulatory elements in components of sarcomeres, Z‑disks, cytoskeletons, desmosomes, and ion channels of cardiomyocytes is provided. The role of pathogenic gene variants associated with mechanisms contributing to the initiation, clinical manifestation, and prognosis of dilated cardiomyopathy is summarized. The causal relationships of mutations in the relevant genes with various clinical scenarios of dilated cardiomyopathy are shown: onset of the diseases, structural myocardial disorders, arrhythmogenic complications, and progression of heart failure. Genetic analysis has become a stimulus for enriching the classification spectrum of cardiomyopathies through the creation of new terms. Specific forms of cardiomyophaties include desmosomal‑dependent cardiomyophathy, desmoplakin cardiomyophathy, RBM20 cardiomyophathy, and others. The argumentation for the further introduction of genetic testing into clinical practice is underlined for the purpose of personalized management of patients with cardiomyopathies and timely identification of risk factors for the disease in their family members at the pre‑nosological stage.
International Journal of General Medicine · 2025 · 0 citations · open access
Traditional Chinese Medicine Treating Dilated Cardiomyopathy: A Literature Review
AbstractDilated cardiomyopathy (DCM), as a difficult problem in modern medical treatment, has become an important cardiovascular disease threatening human beings all over the world with an increasing incidence rate and mortality. Conservative drug therapy is mainly used in clinical practice, but due to unavoidable adverse reactions such as low blood pressure, it is often difficult to achieve satisfactory prognosis. Traditional Chinese medicine has the characteristics of syndrome differentiation and multi-target treatment for DCM, with few adverse reactions and certain advantages. It has achieved good therapeutic effects in clinical practice. Therefore, we summarized and analyzed the clinical evidence and mechanism of traditional Chinese medicine in the treatment of DCM, and combined with the current research status of this disease to analyze the problems and shortcomings, in order to provide more ideas and methods for the treatment of DCM with traditional Chinese medicine.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
